Nephrology Times
LightNews LightNews
banner
nephtimes.bsky.social
Nephrology Times
@nephtimes.bsky.social
1.4K followers 770 following 600 posts
Delivering the latest news in nephrological treatments and technologies with the goal of better informing care decisions and improving patient outcomes
Posts Replies Media Videos
nephtimes.bsky.social
In the final part of their conversation with @annagaddy.bsky.social, @garysinger.bsky.social and @robertblaser.bsky.social of the Renal Physicians Association discuss the policy issues nephrologists should watch. #nephrology #nephsky #publicpolicy
www.docwirenews.com/post/public-...
Public Policy and Nephrology: What to Watch | Docwire News
Anna Gaddy, MD, of Nephrology Times, and Gary Singer, MD, and Robert Blaser of Renal Physicians Association discussed policy issues nephrologists should watch closely in 2026.
www.docwirenews.com
January 23, 2026 at 2:39 PM
nephtimes.bsky.social
Is IVIG finally something that works in chronic active AMR?
A multicenter RCT suggests better graft stability vs standard care alone.
#AMR #graftrejection #kidneytransplant #transplantation #nephrology #nephsky
www.docwirenews.com/post/ivig-li...
IVIG Linked to Stabilized Graft Function in Chronic Active AMR | Docwire News
Intravenous immunoglobulin stabilizes graft histology and slows glomerular filtration rate (GFR) decline in kidney transplant recipients with antibody-mediated rejection (AMR).
www.docwirenews.com
January 22, 2026 at 5:05 PM
nephtimes.bsky.social
In part 2 of their conversation, @garysinger.bsky.social and @robertblaser.bsky.social of the Renal Physicians Association discuss #publicpolicy priorities for #nephrology in 2026 with @annagaddy.bsky.social. #nephsky www.docwirenews.com/post/public-...
Public Policy and Nephrology: Priorities for 2026 | Docwire News
Anna Gaddy, MD, of Nephrology Times spoke with Gary Singer, MD, and Robert Blaser of the Renal Physicians Association about nephrology-related public policy priorities for 2026.
www.docwirenews.com
January 21, 2026 at 7:33 PM
nephtimes.bsky.social
Our own @annagaddy.bsky.social sat down with @garysinger.bsky.social and @robertblaser.bsky.social of the Renal Physicians Association to talk #publicpolicy and #nephrology. Find out why policy should matter to nephrologists in the first part of their discussion. #nephsky ➡️ tinyurl.com/567xczxc
Public Policy and Nephrology: Why It Matters | Docwire News
Anna Gaddy, MD, of Nephrology Times spoke with Gary Singer, MD, and Robert Blaser of the Renal Physicians Association about the importance of public policy in nephrology.
www.docwirenews.com
January 21, 2026 at 2:45 PM
nephtimes.bsky.social
Should we be using MRAs post–kidney transplant?
A new meta-analysis says:
❌ No measurable benefit
⬆️ Higher hyperkalemia risk
#nephrology #kidneytransplant #transplantation #hyperkalemia #nephsky
docwirenews.com/post/steroid...
Steroidal MRAs Raise Hyperkalemia Risk Without Improving Kidney Transplant Outcomes | Docwire News
Mineralocorticoid receptor antagonists (MRAs) offer no kidney benefit for transplant recipients but quadruple hyperkalemia risk despite preserved graft function.
docwirenews.com
January 20, 2026 at 5:45 PM
nephtimes.bsky.social
💡 Have an idea for a topic Nephrology Times should cover?
📝 Want to contribute?
📣 We want to hear from you!

Leave us a comment or email charlotte[dot]robinson[at]formedics[dot]com
January 17, 2026 at 5:15 PM
nephtimes.bsky.social
🗞️ CATCH UP with kidney news, including an FDA delay for sparsentan in #FSGS, a new #CKD guideline from two government agencies, and more. #nephsky #nephrology #kidneytransplant #kidneydisease www.docwirenews.com/post/kidney-...
Kidney News in Brief: FDA Delay for Sparsentan in FSGS, Decline in Deceased Donors and Transplants | Docwire News
Kidney news includes an FDA delay for sparsentan in FSGS, falling deceased donor and kidney transplant numbers, a new chronic kidney disease (CKD) guideline, new board members NKF.
www.docwirenews.com
January 16, 2026 at 5:25 PM
nephtimes.bsky.social
💥 The new update to KDIGO's #anemia in #CKD guideline (its first since 2012) puts an emphasis on individualized care and emerging therapies. 💊 #kidneydisease #nephrology #nephsky
www.docwirenews.com/post/anemia-...
Anemia in CKD Guideline Emphasizes Individualized Care and Emerging Therapies | Docwire News
KDIGO's 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD) provides recommendations for adults and children.
www.docwirenews.com
January 16, 2026 at 3:00 PM
nephtimes.bsky.social
Kidney transplant recipients receiving MDR-101 achieved immune tolerance, stopping immunosuppression for >2 years with no graft loss or graft-vs-host disease. #nephrology #nephsky #KidneyTransplant www.docwirenews.com/post/cell-th...
Cell Therapy Shows Potential for Reduced Immunosuppression After Kidney Transplant | Docwire News
Cell therapy MDR-101 allowed most human leukocyte antigen-matched kidney transplant recipients to taper off immunosuppression safely.
www.docwirenews.com
January 15, 2026 at 5:45 PM
nephtimes.bsky.social
Nephrologists with opinions (so, all of you):

We’re recruiting for our recurring feature,
“5 Nephrologists, 1 Question.”

Short answers (~100 words), real-world concerns, no lectures.

📧 Email: charlotte[dot]robinson[at]formedics[dot]com

#nephrology #nephsky
January 14, 2026 at 7:45 PM
nephtimes.bsky.social
In a trial in Thailand, no significant differences in health-related quality of life were found between children with stage 5 CKD receiving automated vs continuous ambulatory peritoneal #dialysis. #nephrology #nephsky #PediatricNephrology www.docwirenews.com/post/automat...
Automated PD Has No QOL Advantage for Youth With Stage 5 CKD | Docwire News
Automated peritoneal dialysis (PD) had no significant quality-of-life advantage over continuous ambulatory PD for young patients with stage 5 chronic kidney disease (CKD).
www.docwirenews.com
January 14, 2026 at 6:30 PM
nephtimes.bsky.social
In the ALCHEMIST trial, spironolactone did not reduce major #cardiovascular events in people with kidney failure receiving chronic #hemodialysis. #nephrology #nephsky www.docwirenews.com/post/study-d...
Study Does Not Support Spironolactone Use in Kidney Failure and Hemodialysis | Docwire News
In patients with kidney failure on hemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events.
www.docwirenews.com
January 13, 2026 at 6:15 PM
nephtimes.bsky.social
The SAFE-D pilot trial shows recruitment and adherence are feasible for anticoagulation strategies in people with AF receiving #dialysis. #nephrology #nephsky #AtrialFibrillation www.docwirenews.com/post/pilot-t...
Pilot Trial Shows Feasibility of Large Study on AF Management With Dialysis | Docwire News
Researchers showed the feasibility of a trial comparing anticoagulation strategies in patients with atrial fibrillation receiving dialysis.
www.docwirenews.com
January 12, 2026 at 4:45 PM
nephtimes.bsky.social
Hot takes, but make them #nephrology. 🔥🩺

Looking for clinicians to contribute to a recurring feature:
“5 Nephrologists, 1 Question.”

Short answers. Rotating topics.
More fun than polishing a manuscript.

📧 Email: charlotte[dot]robinson[at]formedics[dot]com

#nephsky
January 10, 2026 at 6:02 PM
nephtimes.bsky.social
In adults with provoked VTE and enduring risk factors, 12 months of low-dose apixaban reduced recurrent clots with a low risk of major bleeding. #nephrology #nephsky #dialysis
www.docwirenews.com/post/apixaba...
Apixaban Safe and Effective for Provoked VTE | Docwire News
In provoked venous thromboembolism (VTE) with enduring risks, 12 months of low-dose apixaban cut recurrent VTE with minimal major bleeding.
www.docwirenews.com
January 9, 2026 at 5:04 PM
nephtimes.bsky.social
In the RENIS cohort, higher physical activity was linked to slower GFR decline and lower risk of accelerated kidney function loss over 11 years. #nephrology #nephsky
www.docwirenews.com/post/physica...
Physical Activity Shows Renal Protective Effects | Docwire News
Physical activity is associated with a slower age-related glomerular filtration rate (GFR) decline and a lower risk for accelerated GFR decline.
www.docwirenews.com
January 8, 2026 at 5:30 PM
nephtimes.bsky.social
In a post hoc ADVOCATE analysis, avacopan improved kidney recovery, reduced relapse, and lowered glucocorticoid toxicity in people with GPA or MPA and kidney involvement. #nephrology #nephsky #granulomatosis #polyangiitis www.docwirenews.com/post/avacopa...
Avacopan Effective for GPA and MPA With Kidney Involvement | Docwire News
A study showed avacopan was effective for treating granulomatosis with polyangiitis and microscopic polyangiitis with kidney disease.
www.docwirenews.com
January 7, 2026 at 7:02 PM
nephtimes.bsky.social
The phase 3 APPEAR-C3G study showed iptacopan significantly reduced proteinuria at 6 months in people with C3 glomerulopathy. #nephrology #nephsky #C3G
www.docwirenews.com/post/iptacop...
Iptacopan Is Safe and Effective for Patients With C3G | Docwire News
Iptacopan showed strong proteinuria reduction in C3 glomerulopathy (C3G) at 6 months when added to supportive care including RAAS inhibition and immunosuppression.
www.docwirenews.com
January 6, 2026 at 6:23 PM
nephtimes.bsky.social
In a national cohort from the Netherlands, 37% of children treated for cancer developed #AKI, which strongly predicted #CKD at 1 year. #nephrology #nephsky www.docwirenews.com/post/kidney-...
Kidney Injury Related to Treatment Among Pediatric Patients With Cancer | Docwire News
Acute kidney injury (AKI) is common among children with cancer and is strongly associated with an increased risk for chronic kidney disease (CKD), a study showed.
www.docwirenews.com
January 5, 2026 at 4:03 PM
nephtimes.bsky.social
Have 10 minutes and an opinion about kidneys? 🫘

We’re seeking contributors for “5 Nephrologists, 1 Question.”

One #nephrology question.
Short answer.

Email: charlotte[dot]robinson[at]formedics[dot]com

#nephsky
January 2, 2026 at 7:15 PM
nephtimes.bsky.social
We are delighted to announce that Anna Gaddy, MD, has joined the Nephrology Times editorial board.
www.docwirenews.com/post/nephrol...
January 2, 2026 at 4:04 PM
nephtimes.bsky.social
New Year’s resolutions tend to fail by February.
Reading Nephrology Times is one you can actually keep.
Happy New Year. 🥂
nephtimes.com
Nephrology Times | Docwire News
Nephrology Times is a leading medical news publication for nephrologists, featuring research and clinical updates, expert commentary, and more.
nephtimes.com
January 1, 2026 at 3:01 PM
nephtimes.bsky.social
Research suggests a validated risk-prediction tool can estimate an individual patient’s likelihood of survival with conservative care compared with dialysis in advanced chronic kidney disease.

Read more on Nephrology Times. 👉 www.docwirenews.com/post/predict...
#nephrology #ckd #kidneydisease
Prediction Tool Identifies Mortality Risk for Patients With Advanced CKD | Docwire News
A risk-prediction tool estimated a patient’s likelihood of survival with conservative care compared with dialysis in the treatment of advanced chronic kidney disease (CKD).
www.docwirenews.com
December 31, 2025 at 6:03 PM
nephtimes.bsky.social
Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...
Sparsentan Safe and Effective for Pediatric Patients With FSGS | Docwire News
A subanalysis of DUPLEX study data showed sparsentan resulted in proteinuria reduction for pediatric patients with focal segmental glomerulosclerosis (FSGS).
www.docwirenews.com
December 29, 2025 at 5:15 PM
nephtimes.bsky.social
Do you have strong opinions about #nephrology and ~10 minutes? 👀

Participate in our recurring feature: “5 Nephrologists, 1 Question.”
Short (~100 words), practical, clinician-focused answers to a neph question.

📧 Email: charlotte[dot]robinson[at]formedics[dot]com

#nephsky
December 28, 2025 at 6:30 PM